Studies conducted between 2018 and 2020 have shown that elevated levels of certain microRNAs (miR-381, miR-206, miR-494, miR-154, miR-23b, miR-26b) have a negative impact on the expression of NAMPT in breast cancer [46,47,48], pancreatic cancer [49], melanoma [50], and colorectal cancer [51]. This evidence concerns the gene NAMPT and pancreatic neoplasm.